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Translational Relevance 
Insulin-like growth factor 1 receptor (IGF-1R) signaling is implicated in prostate 
carcinogenesis, and preclinical and clinical studies have shown that targeting IGF-1R 
has antitumor activity in prostate cancer models. Figitumumab is a human IgG2 
monoclonal antibody that binds and downregulates IGF-1R. In a pre-prostatectomy 
study in treatment-naïve patients, single-agent figitumumab markedly reduced prostate-
specific antigen (PSA) levels. These data led to a randomized phase II trial in 
chemotherapy-naïve castration-resistant metastatic prostate cancer patients. Patients 
received either docetaxel/prednisone plus figitumumab, or docetaxel/prednisone alone, 
with crossover at progression. The addition of figitumumab to docetaxel/prednisone did 
not provide benefit, but antitumor activity was observed in patients who progressed on 
docetaxel/prednisone alone and crossed over to docetaxel/prednisone plus 
figitumumab. Further research on the blockade of  
IGF-1R/PI3K/AKT signaling is merited in advanced prostate cancer, perhaps particularly 
in SPOP-mutated disease where raised SRC3 levels generate high IGF ligand levels, in 
combination with next-generation AR targeting drugs. 
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Abstract 
Background: Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like 
growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. This phase 
II trial randomized chemotherapy-naïve men with progressing castration-resistant 
prostate cancer to receive figitumumab every 3 weeks with docetaxel/prednisone (Arm 
A) or docetaxel/prednisone alone (Arm B1). At progression on Arm B1, patients could 
cross over to the combination (Arm B2). 
Methods: Prostate-specific antigen (PSA) response was the primary endpoint; 
response assessment on the two arms was non-comparative and tested separately; 
H0=0.45 vs. HA=0.60 (α=0.05; β=0.09) for Arm A; H0=0.05 vs. HA=0.20 (α=0.05, β=0.10) 
for Arm B2. A comparison of progression-free survival (PFS) on Arms A and B1 was 
planned.  
Results: 204 patients were randomized and 199 treated (Arm A: 97; Arm B1: 102); 37 
patients crossed over to Arm B2 (median number of cycles started: Arm A=8; B1=8; 
B2=4). PSA responses occurred in 52% and 60% of Arms A and B1, respectively; the 
primary PSA response objective in Arm A was not met. Median PFS was 4.9 and 7.9 
months, respectively (hazard ratio 1.44; 95% confidence interval [CI]: 1.06–1.96). PSA 
response rate was 28% in Arm B2. The figitumumab combination appeared more toxic, 
with more treatment-related grade 3/4 adverse events (75% vs. 56%), particularly 
hyperglycemia, diarrhea, and asthenia, as well as treatment-related serious adverse 
events (41% vs. 15%), and all-causality grade 5 adverse events (18% vs. 8%). 
Conclusion: IGF-1R targeting may merit further evaluation in this disease in selected 
populations, but combination with docetaxel is not recommended.  
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Introduction 
Prostate cancer is the second most common male cancer diagnosed globally, and the 
third leading cause of death among men in developed countries (1). Targeting androgen 
receptor signaling remains the standard of care in advanced prostate cancer (2, 3), 
reducing prostate-specific antigen (PSA) expression, inducing tumor regression, and 
relieving symptoms. However, PSA levels eventually increase in many patients, 
suggestive of re-activation of androgen-receptor (AR) signaling and progression to 
castration-resistant prostate cancer (CRPC). Ligand-dependent and -independent 
resistance mechanisms have been described; postulated ligand-independent 
mechanisms include AR splice variants, AR modulation by kinase signaling, and 
epithelial–mesenchymal transition (3).  
 
Until recently, the main treatment for CRPC was docetaxel once every 3 weeks (q3w) in 
combination with prednisone, which is associated with a modest median overall survival 
of 19 months (4, 5). Recently, cabazitaxel (a cytotoxic chemotherapy) (6), abiraterone 
(an inhibitor of androgen biosynthesis) (7), enzalutamide (8), radium-223 (9), and 
sipuleucel-T (an active cellular immunotherapy) (10) have proven efficacious for this 
disease. Despite these advances, treatment options for men with CRPC remain limited. 
The insulin-like growth factor (IGF) pathway is required for normal growth and 
development, and is linked with carcinogenesis (11). In prostate cancer, the IGF 
pathway and androgen receptor signaling interact in multiple ways, with elevated IGF-1 
receptor (IGF-1R) concentration being associated with increased risk of prostate cancer 
(12–16). Aberrant IGF-1R signaling through the PI3K/AKT pathway is implicated in 
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prostate carcinogenesis through loss of phosphatases, including phosphatase and 
tensin homolog (PTEN). Circulating IGF-1 also promotes androgen-responsive growth 
in human prostate cancer cell xenografts (17). Elevated expression of IGF-1 mRNA, as 
well as increased IGF-1R mRNA expression levels, have been correlated with 
progression of human prostate cancer models to androgen independence (18, 19). 
Furthermore, not only has IGF-1 been shown to directly activate the androgen receptor 
in the absence of androgens in prostatic tumor cell lines (20), contributing to the failure 
of androgen deprivation therapy and the development of CRPC, but components of the 
IGF pathway may be required elements for androgen-induced gene expression. This is 
supported by the reduced PSA accumulation and tumor growth observed in IGF-1 
deficient human prostate cancer cell xenografts (17).  
 
Figitumumab (CP-751,871) is a fully human IgG2 monoclonal antibody that binds and 
downregulates IGF-1R, the main receptor in the IGF signaling pathway (21). In an 
androgen-independent model of prostate tumor growth, blockade of IGF-1R not only 
induced cell cycle arrest, but also down-regulated androgen-regulated gene expression 
and was associated with decreased AR nuclear localization (22, 23). IGF-1R blockade 
also increases sensitivity to chemotherapy tumor cell kill with cytotoxic chemotherapies 
in preclinical models (21, 24). In a phase Ib study that included 22 patients with 
advanced CRPC, figitumumab with docetaxel was well tolerated with promising 
antitumor activity (25). Moreover, figitumumab had antitumor activity as a single agent in 
newly diagnosed hormone-therapy naïve patients awaiting prostatectomy (26). Based 
on these findings, this randomized phase II study (NCT00313781) was undertaken to 
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assess the efficacy of figitumumab in combination with docetaxel/prednisone in 
chemotherapy-naïve patients with metastatic CRPC. 
 
Patients and Methods 
Patients 
Patients with histologically confirmed prostate cancer and evidence of metastatic 
disease either on bone scans or computed tomography who were  
chemotherapy-/radioisotope-naïve were included. For trial entry, CRPC was defined as 
disease progression after at least one hormonal treatment, with castrate levels of 
testosterone (<50 ng/dL or <1.7 nmol/L). Disease progression was defined as any of the 
following: an increase in PSA >50% over nadir on hormonal therapy according to the 
Prostate-Specific Antigen Working Group (PSAWG) criteria published in 1999 (27); 
disease progression as defined by Response Evaluation Criteria in Solid Tumors 
(RECIST version 1.0) (28); or ≥2 new bone lesions.  
 
Additional eligibility criteria included: concurrent luteinizing hormone-releasing hormone 
(LHRH) agonist if the patient was not surgically castrated; Eastern Cooperative 
Oncology Group (ECOG) performance status of ≤2; any adverse events (AEs) from 
prior cancer therapy resolved to National Cancer Institute (NCI) Common Terminology 
Criteria for Adverse Events (CTCAE; version 3.0) grade ≤1 or not considered a safety 
risk by sponsor and investigator; stable pain level; and adequate hematologic and blood 
chemistry parameters.  
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Patients were excluded if they had received anti-androgen therapy within 4–6 weeks of 
study start (dependent on the therapy); radiation to >25% of bone marrow; local 
radiation within 2 weeks; chronic high-dose immunosuppressive steroids within  
2 weeks; or products known to affect PSA level. 
 
The study was conducted according to the Declaration of Helsinki and the International 
Conference on Harmonization Good Clinical Practice guidelines. The study protocol 
was approved by the local regulatory authorities and institutional review boards at all 
participating institutions. Signed, informed consent was obtained from all patients before 
study entry. 
 
Study design and treatment 
This was a randomized, open-label, two-arm, phase II study conducted at 16 sites. 
Patients were randomly assigned in a 1:1 ratio to receive either figitumumab 20 mg/kg 
(or 10 mg/kg before protocol amendment #3 in February 2007) by intravenous (IV) 
infusion plus docetaxel 75 mg/m2 by infusion and prednisone 5 mg twice daily (Arm A), 
or docetaxel/prednisone (Arm B1) q3w. Patients randomized to docetaxel/prednisone 
alone were able to cross over to receive figitumumab and docetaxel/prednisone 
(combination treatment) following disease progression (Arm B2). Inhibition of tubulin 
function by docetaxel has been shown to impact AR function and block cytoplasmic-to-
nucleus shuttling of the AR (29). This in turn can upregulate signaling through the IGF-
1R/PI3K/AKT axis. Therefore, there was a strong mechanistic rationale for pursuing this 
crossover. In order to be eligible to cross over, patients receiving docetaxel/prednisone 
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must have satisfied one of the following criteria within 6 weeks from the last docetaxel 
administration after at least 3 courses of docetaxel: disease progression demonstrated 
by ≥2 new bone lesions, RECIST progression, PSA progression (defined in the next 
section), or increased pain at the metastatic site requiring >2 weeks of narcotics, 
radiation, or doubling the dose of corticosteroids.  
 
All study drugs were started on day 1 of each 3-week cycle. Protocol-specified 
treatment interruptions and dose reductions were permitted to manage AEs. No more 
than two dose reductions of docetaxel were permitted (to 60 mg/m2 and 45 mg/m2). 
Figitumumab treatment could be delayed by up to one cycle (6 weeks from previous 
dose) for treatment-related toxicities. A maximum of two dose reductions of figitumumab 
were permitted (to 10 mg/kg and 6 mg/kg).  
 
Treatment continued until disease progression (biochemical, clinical, or imaging), 
unacceptable toxicity, or completion of 12 months of treatment (unless there were 
compelling reasons to continue). Patients with disease progression determined by PSA 
levels alone could continue treatment if it was deemed to be providing a clinical benefit, 
as could those with worsening bone scans. 
 
Study endpoints and assessments 
The primary endpoint was PSA response (defined below) in both Arm A and Arm B2. 
Secondary endpoints included progression-free survival (PFS), safety, and biomarker 
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evaluation, including the effect of study drug on the total number of circulating tumor 
cells (CTCs). 
 
To acquire these data, a PSA baseline reference value was obtained from blood 
samples taken prior to the first dose of study drug. Additional samples were taken on 
day 15 of each cycle, again at the end of treatment, and during the follow-up visit. The 
primary efficacy summary measure was PSA response rate, where PSA response was 
defined as best response of either PSA normalization or partial PSA response. 
The categories of best response were: PSA normalization, partial PSA response, PSA 
progression, stable PSA response, RECIST progression, symptomatic deterioration, 
early death, and indeterminate. PSA normalization was defined as PSA ≤0.2 ng/mL on 
two successive evaluations at least 3 weeks apart and no imaging or clinical evidence 
of disease progression. Partial PSA response was defined as ≥50% decrease in PSA 
from baseline (defined as the last PSA value before crossover for patients entering Arm 
B2), on two successive evaluations at least 3 weeks apart and no imaging or clinical 
evidence of disease progression. PSA progression was defined at the timepoint when 
PSA increased on 2 successive evaluations taken 1 week apart after dosing in cycle 3, 
and was defined as follows: 1) an increase in PSA ≥50% and ≥5 ng/mL above the nadir 
of all on-study evaluations prior to the current evaluation, for subjects who achieved 
PSA response earlier during study; 2) an increase in PSA ≥25% over baseline, for 
subjects whose PSA had not decreased on study; 3) an increase in PSA ≥25% and ≥5 
ng/mL over the nadir of all on-study evaluations prior to the current evaluation, for 
patients whose PSA had decreased on study but had not met criteria for PSA response. 
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Stable PSA response was defined as PSA changes documented at least 6 weeks after 
enrollment that did not meet the criteria for PSA normalization, partial PSA response or 
confirmed PSA progression.  
 
RECIST progression was defined as the best response when objective progression per 
RECIST was documented within 12 weeks from enrollment and the patient did not 
qualify for any of the best responses defined above. Symptomatic deterioration was 
defined as the best response when a patient discontinued treatment due to global 
deterioration in health status within 12 weeks from enrollment and did not qualify for any 
of the best responses defined above. Early death was defined as the best response 
when a patient died within 6 weeks from enrollment and did not qualify for any of the 
best responses defined above. Finally, indeterminate was defined as the best response 
when none of the best responses defined above were applicable. 
 
PFS was defined as the time from randomization to first event of disease progression, 
which was defined as one or more of the following: confirmed PSA progression; ≥2 new 
bone lesions; progressive disease according to RECIST; increased pain requiring one 
or more of the following: narcotics for >2 weeks, radiation therapy, doubling the 
corticosteroid dose, radionuclide therapy, or palliative chemotherapy; intervention for 
any prostate cancer-related events (e.g. radiation, surgery); new symptoms related to 
tumor growth; or death due to any cause. Patients were followed until disease 
progression irrespective of whether they were receiving study drug prior to progression.  
Research. 
on January 16, 2019. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 17, 2014; DOI: 10.1158/1078-0432.CCR-13-1869 
 Page 12 of 39 
For enumeration of CTCs, blood samples were collected at screening, approximately 30 
minutes before dosing in odd numbered cycles and at end of treatment. The CTCs were 
enumerated using the CellSearch system (Immunicon) as previously described (30). 
Patients enrolled in this study were not required to have measurable disease; however, 
disease assessment was undertaken to document imaging evidence of progression.  
 
Statistical analysis 
This study evaluated the PSA response rate of the combination of figitumumab with 
docetaxel/prednisone in chemotherapy-naïve patients (Arm A). The primary efficacy 
endpoint, PSA response, was evaluated in all patients who received at least one dose 
of study drug (except those who discontinued prior to cycle 3 due to PSA progression 
only) and had a baseline PSA reference value. In Arm A, the null hypothesis was H0: P 
≤ 0.45 and the alternative was HA: P > 0.45, where P is the probability of PSA response. 
Since the hypotheses were one-sided, testing was done at one-sided level P = 0.05. 
With a planned sample size of 100, the study had power 91% for an alternative of P = 
0.6. If the null hypothesis was rejected at the one-sided 0.05 significance level, 
figitumumab would be considered active in this setting. 
 
This study also evaluated the PSA response rate of combination treatment after 
progression on docetaxel/prednisone alone (Arm B2). A 40-patient, two-stage design 
(31) was used to test the null hypothesis H0: P ≤ 0.05 versus the alternative HA: P > 
0.05, ensuring 5% probability of type I error and 90% power for an alternative of 0.2. 
Twenty patients receiving combination treatment after progression on 
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docetaxel/prednisone alone were to be enrolled in the first stage; if one or more PSA 
responses were observed among them, an additional 20 patients receiving combination 
treatment were to be recruited. If five or more responses were observed among the 40 
patients in Arm B2, the null hypothesis would be rejected.  
 
Finally, to further explore efficacy of the regimen, a comparison of PFS on Arm A with 
PFS on Arm B using a 1-sided 0.1 significance level log-rank test was planned. If the 
true A/B hazard ratio (HR) were 0.67, the sample size would be large enough for 
adequate (90%) power to conclude regimen A to be of interest. Kaplan–Meier methods 
were used for estimation. The HR and 95% confidence interval (CI) were generated 
using proportional hazards regression modeling.  
 
Results 
Between October 2006 and July 2009, 204 patients were randomized equally between 
Arm A and Arm B1, of whom 199 were treated (97 on Arm A and 102 on Arm B1). Five 
patients in Arm A received figitumumab 10 mg/kg as starting dose before protocol 
amendment #3 in February 2007, while the other 92 patients in Arm A received 
figitumumab 20 mg/kg as starting dose. Patient demographics and baseline disease 
characteristics are presented in Table 1. The most frequently involved metastatic site 
was bone. Eighty-seven of 102 patients in Arm A were PSA response evaluable. Among 
the 15 unevaluable patients, five did not have treatment, eight were treated but 
discontinued treatment prematurely (prior to cycle 3 due to PSA progression only), and 
two were without adequate baseline assessment.  
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In Arm B1, 37 patients progressed on docetaxel/prednisone and were crossed over to 
figitumumab plus docetaxel/prednisone (Arm B2); disease progression in these patients 
was based on PSA progression only (n =1 2; 32%), RECIST-defined progression only (n 
= 10; 27%), both PSA and RECIST progression (n = 5; 14%), and other (n = 10; 27%).  
Baseline characteristics of crossover patients were similar to those of Arm A and the 
entire Arm B1 cohort (Table 1). Five crossover patients were not evaluable for the 
primary endpoint: four had an inadequate baseline assessment and one discontinued 
treatment prematurely (Fig. 1). 
 
Study drug exposure 
The study treatments were given in 21-day cycles. The median number of treatment 
cycles started was 8 (range, 1–35 cycles) for Arm A, and 8 (range, 1–32 cycles) for Arm 
B1. In Arm A, the figitumumab infusion was interrupted or cycle delayed in 35 patients 
(36%) because of AEs, and seven patients (7%) required a reduction in the figitumumab 
dose. More patients in Arm A had a docetaxel dosing regimen modification due to AEs 
than in Arm B1; the docetaxel infusion was interrupted or cycle delayed in 38 patients 
(39%) and 14 patients (14%) in  Arms A and B1, respectively, while the docetaxel dose 
was reduced in 28 patients (29%) and 20 patients (20%), respectively. Arm B2 patients 
had had a minimum of three courses and a median of 6 cycles of docetaxel (range, 3–
24 cycles) before crossover following disease progression on docetaxel/prednisone 
alone and went on to start a median of 4 treatment cycles of figitumumab (range, 2–26 
cycles) and a median of 4 treatment cycles of docetaxel (range, 2–13 cycles). Adverse 
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events led to a figitumumab infusion interruption or cycle delay in nine patients (24%) 
and dose reduction in three patients (8%) from Arm B2, and to a docetaxel dosing delay 
in ten patients (27%) and dose reduction in eight patients (22%).   
 
PSA response rate  
In Arm A, none of the patients achieved PSA normalization; 45 (52%) patients had a 
partial PSA response and 27 (31%) patients had a stable PSA response. In Arms B1 
and B2, PSA normalization was reported in 3 (3%) and 1 (3%) patients, respectively; 56 
(57%) and 8 (25%) patients had a partial PSA response; and 21 (21%) and 9 (28%) 
patients had a stable PSA response. 
 
The PSA response rate (PSA normalization plus partial PSA response; primary 
endpoint) was 52% (90% CI: 42.4–61.0) and 60% (90% CI: 51.4–68.5) in patients in 
Arm A and Arm B1, respectively (Table 2). Given that 87 patients in Arm A were PSA 
response evaluable, 48 or more observed PSA responses in Arm A were required to 
reject the null hypothesis at 1-sided significance level 0.05. Since 45 PSA responses 
were observed in Arm A, corresponding to a 1-sided P-value of 0.125, the primary PSA 
response objective in Arm A was not met (i.e. there was no statistically significant 
evidence to conclude that Arm A had a PSA response rate greater than 45%).   
 
For patients in Arm B2, a true PSA response probability of 0.20 or greater would be of 
interest while a true PSA response probability of 0.05 or lower would not. Nine of 32 
PSA evaluable patients were responders. The PSA response rate was 28% (90% CI: 
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15.5–43.9) (Table 2), corresponding to a 1-sided P-value of < 0.001; hence, the addition 
of figitumumab yielded a PSA response rate significantly greater than the null value of 
5% in patients who had progressed on docetaxel/prednisone. Maximal PSA percent 
reductions from baseline are shown in Fig. 2. 
 
CTCs 
In total, 46 patients in Arm A and 39 patients in Arm B1 had ≥5 CTCs per 7.5 mL blood 
at baseline (Table 1). The number of CTCs appeared to drop in both arms through 
cycles 1–5, although this was most marked in patients receiving docetaxel/prednisone 
alone: the mean percentage decrease in CTCs from baseline at cycle 5 was 23% in the 
figitumumab plus docetaxel/prednisone arm and 41% in patients receiving 
docetaxel/prednisone alone. Analyses of CTCs were not pursued at cross-over. 
 
PFS 
In Arms A, B1, and B2, respectively, 88 (91%), 77 (75%), and 31 patients (84%) had 
experienced a progression event at the time of analysis. In the majority of cases, these 
events were related to objective (PSA or RECIST-defined) progression; 87 patients 
(90%) in Arm A, 77 patients (75%) in Arm B1, and 30 patients (81%) in Arm B2 had 
objective progression. The remaining type of progression event was patient started a 
new treatment, with progression unknown (Arm A, n = 1; Arm B2, n = 1). Two patients 
withdrew their consent for additional follow-up before progression (Arms A and B1, n = 1 
each), and three patients in Arm B1 started a new treatment without progression. 
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Median PFS after 171 events was 4.9 months (95% CI: 4.1–5.9) for patients in Arm A 
and 7.9 months (95% CI: 6.0–8.9) for patients in Arm B1 (HR 1.442, 95% CI: 1.060–
1.961, 2-sided log-rank test P = 0.019 [1-sided log-rank test P = 0.991]; Fig. 3). These 
data demonstrate that the results favor Arm B1. For patients in Arm B2, median PFS 
was 4.0 months (95% CI: 3.3–4.8). 
 
Safety 
Overall, there were more treatment-related grade 3/4 AEs in Arm A than in Arm B1 
(75% vs. 56%). In patients receiving figitumumab plus docetaxel/prednisone, 
neutropenia (not counting febrile neutropenia) was the most frequent grade 3/4 
treatment-related AE (32%; Table 3). The incidence of grade 3/4 treatment-related 
neutropenia observed in Arms A and B1 was similar (32% and 33%, respectively). A 
clinically meaningful difference between Arms A and B1 was observed in the number of 
subjects with the following treatment-related AEs: diarrhea (57.7%, 33.3%), decreased 
appetite (49.5%, 25.5%), fatigue (42.3%, 34.3%), asthenia (36.1%, 27.5%), 
hyperglycemia (33.0%, 13.7%), stomatitis (18.6%, 7.8%), muscle spasm (15.5%, 4.9%), 
and febrile neutropenia (12.4%, 6.9%). 
 
More treatment-related serious adverse events (SAEs) were reported in patients 
receiving figitumumab plus docetaxel/prednisone compared with docetaxel/prednisone 
alone (41% vs. 15%). Febrile neutropenia was the most common SAE in both treatment 
arms (12% vs. 7%). In addition, 10 (27%) of 37 patients who progressed on 
docetaxel/prednisone had treatment-related SAEs while subsequently receiving 
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figitumumab plus docetaxel/prednisone. In total, 17 (18%) grade 5 all-causality AEs 
were reported in the figitumumab plus docetaxel/prednisone Arm A, compared with 8 
(8%) in the docetaxel/prednisone alone Arm B1. Only one grade 5 all-causality AE was 
considered to be treatment-related: hypovolemic shock related to nausea, vomiting, and 
diarrhea occurring in a patient receiving figitumumab plus docetaxel/prednisone. 
 
Treatment-related AEs were the primary reason for treatment discontinuation in 15 
(15%) and 12 (12%) patients in Arms A and B1, respectively, and in 4 (11%) patients in 




In this phase II study, combining the anti-IGF-1R monoclonal antibody, figitumumab (20 
mg/kg, IV), with the standard regimen of docetaxel/prednisone did not improve the PSA 
response rate significantly above the null value of 45% in chemotherapy-naïve patients. 
Similarly, the addition of figitumumab appeared to have a detrimental impact on PFS 
compared with docetaxel/prednisone alone: median PFS was 4.9 months (95% CI: 4.1–
5.9) versus 7.9 months (95% CI: 6.0–8.9). The calculated HR was 1.442 (95% CI: 
1.060–1.961), favoring docetaxel/prednisone alone. Overall survival data were not 
collected. These findings are disappointing given the encouraging declines in PSA 
expression following treatment with single-agent figitumumab in a single-center, phase 
II study of 14 patients with localized prostate cancer (26). Nevertheless, a PSA 
response of 28% (90% CI: 15.5–43.9) was observed in patients treated with the 
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combination after disease progression with docetaxel/prednisone alone, suggesting that 
IGF-1R blockade may have some activity in this disease. The implications of these PSA 
falls are unclear; docetaxel has been implicated in impacting AR signaling and could 
potentially upregulate the IGF-1R/PI3K/AKT axis, thus making the combination with 
figitumumab more active post-docetaxel at cross-over than in the docetaxel-naïve 
patients (19, 32).  
 
Our data highlight the challenges of improving the activity of docetaxel monotherapy in 
the first-line setting of castrate-resistant prostate cancer. Docetaxel has been combined 
with many biological agents with distinct mechanisms of action including tyrosine kinase 
inhibitors, angiogenic inhibitors, BCL-2 inhibitors, and immunologic agents. To date, no 
drug has demonstrated improved overall survival when added to docetaxel in a phase III 
trial, and in some cases the addition proved detrimental to outcomes (33–37). Phase II 
trials such as ours are an important step in adequately evaluating the activity of novel 
agents; several recent phase III trials were started on the basis of phase I/II trial 
expansion cohorts (38).  
 
Toxicity was substantially higher with figitumumab combination treatment than with 
docetaxel and prednisone, with an increased incidence of grade 3/4 treatment-related 
AEs and SAEs reported with the combination treatment compared with 
docetaxel/prednisone alone. Although only one death in the figitumumab combination 
arm was considered treatment-related, it is notable that the rate of grade 5 AEs from 
any cause was higher in both Arms A and B2 (18% and 22%) than in Arm B1 (8%), 
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giving concern that the toxicity of combination treatment may have played a contributory 
factor in some cases. However, it is also possible that the rate of grade 5 AEs was 
under-estimated in Arm B1, since all AEs were attributed to Arm B2 immediately after 
starting figitumumab at crossover. The relatively poor tolerability of the figitumumab 
combination may also account, at least in part, for the inferior efficacy observed in Arm 
A because of under-treatment with docetaxel; AE-related treatment interruptions or 
delays with this agent were more than twice as common in Arm A than in Arm B1, and 
more patients needed a docetaxel dose reduction in Arm A compared with Arm B1. In 
other respects, safety findings in the current study were similar to those known to be 
class effects for IGF-1R inhibitors and previously reported figitumumab-associated AEs 
(25, 39). Hyperglycemia, a known class effect of IGF-1R inhibitors, was reported in 
approximately one-third of the patients in this study, and is likely related to impaired 
homeostatic control of insulin and blood glucose levels following abrogation of IGF-1R 
signaling (40). Other AEs, including neutropenia, were expected toxicities associated 
with taxane treatment.  
 
In conclusion, the primary objective of this study with respect to PSA response in Arm A 
patients with chemotherapy-naïve CRPC receiving figitumumab plus 
docetaxel/prednisone was not met, as there was no statistically significant evidence that 
PSA response in Arm A was greater than 0.45. The primary objective of the study with 
respect to PSA response in Arm B2 patients, however, was met and it was concluded 
that PSA response with the addition of figitumumab after progression on 
docetaxel/prednisone was significantly greater than 0.05. Despite discontinuation of 
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figitumumab clinical development, IGF-1R may still be considered to be a valid 
investigational target for the treatment of prostate cancer. Additional data on the effect 
of targeting IGF-1R have been reported in clinical studies (14, 41), both in patients with 
localized prostate cancer (26) and particularly in patients with advanced CRPC (42, 43). 
Moreover, studies indicate that SPOP mutated CRPC have high steroid receptor co-
activator-3 (SRC3) levels which result in high IGF ligand levels. These data, along with 
recent evidence indicating that the combination of an AKT inhibitor with an antiandrogen 
prolongs disease stabilization in a model of CRPC, provide further evidence for the 
strategy of targeting the AR and the IGF-1R/PI3K/AKT signaling axis (44), and the 
combination of IGF-1R inhibitors with novel endocrine anticancer agents such as 
enzalutamide may therefore prove fruitful in selected CRPC populations (45).  
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TABLES AND FIGURES 
Table 1. Patient characteristics at baseline 
Patient characteristic Figitumumab + 
docetaxel/prednisone  
(Arm A) 




(n = 102) 
Figitumumab + docetaxel/ 
prednisone (crossover 
from B1; Arm B2) 
(n = 37)f 
Mean age, years (SD) 68.9 (7.4) 67.9 (7.5) 66.2 (6.4) 
Ethnic background    
White 94 (92) 97 (95) 35 (95) 
Black 4 (4) 2 (2) 1 (3) 
Other 4 (4) 3 (3) 1 (3) 
ECOG performance status, n (%)    
0 52 (51) 56 (55) 21 (57) 
1 43 (42) 43 (42) 15 (41) 
2 1 (<1) 2 (2) 1 (3) 
Missing 6 (6) 1 (<1) 0 
Measurable disease present, n (%)b 66 (65) 66 (65) 25 (68) 
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Bone 85 (83) 81 (80) 28 (76) 
Pelvis 16 (16) 20 (20) 9 (24) 
Lung 12 (12) 15 (15) 4 (11) 
Liver 13 (13) 12 (12) 1 (3) 
Mediastinum 5 (5) 10 (10) 2 (5) 
Peritoneum 8 (8) 7 (7) 4 (11) 
Otherc 64 (63) 61 (60) 22 (59) 
Number of lesion sites, n (%)    
1 27 (27) 24 (24) 9 (24) 
2 25 (25) 23 (23) 9 (24) 
3 19 (19) 13 (13) 6 (16) 
4 7 (7) 11 (11) 4 (11) 
>4 23 (22) 28 (28) 8 (22) 
Missing 1 (<1) 3 (3) 1 (3) 
Prior surgery, n (%)d 58 (57) 71 (70) 24 (65) 
Prior radiation therapy, n (%)d 59 (58) 65 (64) 24 (65) 
Prior hormonal therapy, n (%)d 93 (91) 96 (94) 34 (92) 
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Mean (SD) 288.0 (500.9) 189.0 (314.4) 169.5 (234.1) 
Median (range) 105.0 (6.1–3683) 96.4 (6.3–2124) 82.5 (0.4–1095) 
Patients with ≥5 CTCs per 7.5 mL, n (%) 46 (45) 39 (38) 17 (46) 
Median number of CTCs per  
     7.5 mL blood (ULQ) 
16.5 (10, 73) 52.0 (20, 192) 65.0 (18, 214) 
aFigitumumab was added to treatment for patients progressed on docetaxel/prednisone alone; bat least one target lesion ≥2 cm 
(>1 cm by spiral computed tomography); cincludes ascites, brain, breast, subcutaneous, and not reported; dnot reported in Arms A 
and B1, respectively, for: prior surgery, n = 1 and n = 3; prior radiation therapy, n = 1 and n = 3 (n = 1 for Arm B2); prior hormonal 
therapy, n = 3 and n = 2 (n = 1 for Arm B2); ebaseline PSA data not available for n = 1 each in Arms A and B1, and for n = 2 in 
Arm B2; fpatient characteristics for Arm B2 are as at the start of the study, not the status at crossover, with the exception of 
baseline PSA which was at time of crossover.  
Abbreviations: CTCs, circulating tumor cells; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; ULQ, upper 
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(crossover from B1) 
(Arm B2) 
(n = 32) 









PSA normalization  0 3 (3) 1 (3) 
Partial PSA response  45 (52) 56 (57) 8 (25) 
Stable PSA 27 (31) 21 (21) 9 (28) 
PSA progression 5 (6) 8 (8) 8 (25) 
RECIST progression 1 (1) 1 (1) 1 (3) 
Symptomatic deterioration 6 (7) 0 (0) 0 (0) 
Early death 2 (2) 1 (1) 0 (0) 
Indeterminate 1 (1) 8 (8) 5 (16) 
aBest responses are defined in the section “Study Endpoints and Assessments”. 
Abbreviations: CI, confidence interval; PSA, prostate-specific antigen; RECIST, Response 
Evaluation Criteria in Solid Tumors. 
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Table 3. Treatment-related adverse events occurring in ≥15% of patients in any treatment group 
 Figitumumab + docetaxel/ 
prednisone (Arm A) 
(n = 97) 
Docetaxel/prednisone alone 
 (Arm B1) 
(n = 102) 
Figitumumab + docetaxel/ 
prednisone (crossover from B1) 
(Arm B2) 
(n = 37) 
Incidence, n (%) All grades Grade ≥3 All grades Grade ≥3 All grades Grade ≥3 
Diarrhea 56 (58) 13 (13) 34 (33) 0 10 (27) 0 
Decreased appetite 48 (50) 4 (4) 26 (26) 1 (1) 17 (46) 3 (8) 
Alopecia 46 (47) 5 (5) 51 (50) 3 (3) 17 (46) 2 (5) 
Fatigue 41 (42) 9 (9) 35 (34) 8 (8) 13 (35) 5 (14) 
Neutropenia 39 (40) 31 (32) 39 (38) 34 (33) 10 (27) 9 (24) 
Dysguesia 36 (37) 1 (1) 37 (36) 0 12 (32) 0 
Asthenia 35 (36) 10 (10) 28 (28) 4 (4) 13 (35) 3 (8) 
Hyperglycemia 32 (33) 23 (24) 14 (14) 4 (4) 14 (38) 8 (22) 
Nausea 28 (29) 3 (3) 26 (26) 0 8 (22) 0 
Leukopenia 22 (23) 12 (12) 25 (24) 14 (14) 3 (8) 1 (3) 
Stomatitis 18 (19) 1 (1) 8 (8) 2 (2) 0 2 (5) 
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Muscle spasm 15 (16) 0 5 (5) 0 5 (14) 0 
Neuropathy peripheral 14 (14) 1 (1) 21 (21) 2 (2) 12 (32) 1 (3) 
Lethargy 12 (12) 3 (3) 15 (15) 0 5 (14) 0 
Vomiting 12 (12) 1 (1) 9 (9) 1 (1) 7 (19) 0 
Edema peripheral 6 (6) 0 17 (17) 0 3 (8) 0 
Anemia 6 (6) 0 16 (16) 0 6 (16) 1 (3) 
Dyspnea 6 (6) 0 16 (16) 0 3 (8) 1 (3) 
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Abbreviations: BID, twice daily; PSA, prostate-specific antigen; q3w, every 3 weeks; RECIST, 
Response Evaluation Criteria in Solid Tumors. 
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Reasons for missing patients include: no baseline record and/or no on-study records (Arm A, 
Arm B1), no (crossover) baseline record (Arm B2). Abbreviation: PSA, prostate-specific antigen. 
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